Co-founder, Chief Innovation and Strategy Officer at Vaccibody AS.
Oslo, Norway
Joined February 2010
- Tweets573
- Following235
- Followers612
- Likes861
Når grundertilværelsen føles ekstra meningsfull🌟 ringvirkninger.dnb.no/vis/99…
We select our partners carefully! Enjoy the collaboration with the competent team at Adaptive Biotechnologies generating 3rd generations vaccines. Listen to the webcast at 4 pm today. bit.ly/36uEsEl
This is an amazing achievement by the entire Vaccibody family! Thanks to the patients, investigators, collaborators and all Vaccibody team members for the dedication to this important study. vaccibody.com/wp-content/upl…
Proud and excited for reaching this milestone! Rewarding to work with JZ and the rest of the Nektar team.
We are excited to announce we reached an important milestone in our partnership with Vaccibody, dosing the first patient in our Phase 1/2a study arm evaluating the combination of bempeg with VB10.NEO. Read more: bit.ly/3afAVei
Very excited about the strong signs of vaccine-induces clinical responses, backed up with a range of scientificly sound correlations, in our cancer neoantigen vaccine trial!
lnkd.in/eP4csKp #cancerresearch #cancervaccine #neoantigens
New times in Vaccibody! Thx to Martin for 4 great years! And a warm welcome to Michael! Ready for next phase💪🏼 vaccibody.com/organizational…
Thanks for the invite and opportunity to share my journey. Really enjoyed the entire program and the interactive discussions!
Last fireside chat before our Panel! Wonderful to have @Vaccibody President & CSO Agnete Fredriksen sharing with us - “How to manage the #science of a #biotech company”!
Agnete B. Fredriksen retweeted
🎤 Speaker #1 - We're thrilled to have Agnete Fredriksen @ABFredriksen, CSO of @Vaccibody, join us at Labiotech Insider Day! Take a sneak peek at the program & register today! 👉🏻 bit.ly/2KHPWLe 👈🏻 #biotech #LBRefresh
In San Francisco speaking at the Mol Med Tri-Con while TV2 tells about our Roche collaboration. Exciting days. tv2.no/nyheter/10466278/
And then the 230 MNOK was secured! Thanks for the strong support and interest from our investors!
vaccibody.com/sucessfully-cl…
Vaccibody is excited to announce a Collaboration With Roche combining VB10.16 and Atezolizumab in Cervical Cancer!
vaccibody.com/vaccibody-as-r…
Agnete B. Fredriksen retweeted
NRK EKKO har laget et flott radioinnslag om vår porteføljebedrift Vaccibody der @ABFredriksen forteller om hvordan de utvikler persontilpassede kreftvaksiner: radio.nrk.no/serie/ekko#t=58… #helsenæring #kreft
Agnete B. Fredriksen retweeted
We’ve entered into a new clinical collaboration with Vaccibody to combine their personalized neo-antigen cancer vaccine with NKTR-214. Learn more about this combination's design to harness specific T cell clonal expansion in the fight against cancer: bit.ly/2xqtkr6
So excited to announce this highly interesting clinical collaboration with Nektar Therapeutics! vaccibody.com/vaccibody-anno…
Trying to convince our Minister of Trade and Industry to create better incentiver for startup and founders:-) #timeforchange #startup #politicians
Agnete B. Fredriksen retweeted
Ny pod er ute nå. @elikirand har besøk av @ABFredriksen og Martin Bonde fra vår porteføljebedrift #Vaccibody: Vi snakker om utviklingen av deres persontilpassede kreftvaksine og planer for framtiden soundcloud.com/user-97220871…
Agnete B. Fredriksen retweeted
– Vi skreddersyr kreftvaksiner til hver pasient. Vi tar immunterapi ett skritt videre, og bruker kunnskapen til å utvikle enda mer persontilpasset medisin, sier president og grunnlegger av #Vaccibody, @ABFredriksen, til VG. vg.no/i/6nKj0L
